The CE mark will take what it takes but the real win will come with the results of the trials, PanCO and OncoPaC-1. Making a realistic chance of recovery from Pancreatic Cancer (PC) will be the dramatic leverage. See the Annual Report. Currently PC has only a 1% chance of recovery with a 5% chance of surviving 5 years. What this device is looking like doing, providing a real %age chance of not only surviving longer but full recovery for others, will make this device invaluable and testable for a whole range of cancers. If it takes a few months to get there, who cares.
The CE mark will take what it takes but the real win will come...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9286 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 412 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |